A population-based series of uterine carcinosarcomas with long-term follow-up

Acta Oncologica

Volumn 52, Issue 4, 2013, Pages 759-766

  Sorbe, Bengt ^a   Paulsson, Gunnar ^b   Andersson, Solveig ^c   Steineck, Gunnar ^d  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

^c Department of Gynecology and Obstetrics ^*  (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CARCINOSARCOMA; FEMALE; FOLLOW UP; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; UTERINE CARCINOSARCOMA; UTERUS CANCER; ABDOMINAL CANCER; ADJUVANT CHEMORADIOTHERAPY; BLADDER DISEASE; BONE METASTASIS; CANCER STAGING; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM METASTASIS; DISTANT METASTASIS; ENTEROPATHY; EXCISION; EXTERNAL BEAM RADIOTHERAPY; GEOGRAPHIC DISTRIBUTION; HUMAN TISSUE; LAPAROTOMY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MULTIMODALITY CANCER THERAPY; PELVIS TUMOR; POPULATION; PREOPERATIVE CARE; PROPHYLAXIS; RADIATION SICKNESS; RADICAL HYSTERECTOMY; RECURRENCE RISK; REGIONAL METASTASIS; SURVIVAL RATE; SURVIVAL TIME; TISSUE REACTION; TUMOR RECURRENCE; UTERUS CARCINOSARCOMA; UTERUS SARCOMA; VAGINA CANCER;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CARCINOSARCOMA; CHEMORADIOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; MIDDLE AGED; SURVIVORS; TREATMENT OUTCOME; UTERINE NEOPLASMS;

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CISPLATIN; DACARBAZINE; TAXANE DERIVATIVE;

EID: 84875944999     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.724179     Document Type: Article

References (33)

1. Tavassoli FA, Devilee P, e ditors. World Health Organization Classification of tumours. In: Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003.
2. Disaia PJ, Creasman WT. Sarcoma of the uterus. In: D isaia PJ, Creasman WT, editors. Clinical gynecologic oncology. St. Louis: Mosby; 2002.
3. Livi L, Paiar F, S hah N, B lake P, V illanucci A, A munni G, et al. Uterine sarcoma: Twenty-seven years of experience. Int J Radiat Oncol Biol Phys 2003; 57: 1366-73.
4. Major FJ, Blessing JA, S ilverberg SG, Morrow CP, Creasman WT, Currei JL, et al. Prognostic factors in early stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 1993; 71: 1702-9.
5. Chi D S, M ychalczak B, Saigo P E, Recigno J, B rown C L. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol 1997; 65: 493-8.
6. WHO. Pathology and genetics of tumors of the breast and female genital organs. Lyon: IARC Press; 2003.
7. Benoit L, A rnould L, C heynel N, G oui S, C ollin F, Fraisse J, et al. The role of surgery and treatment trends in uterine sarcoma. Eur J Surg Oncol 2005; 31: 434-42.
8. Arrastia C D, Fruchter R G, C lark M, M aiman M, Remy J C, Macaset M, et al. Uterine carcinosarcomas: Incidence and trends in management and survival. Gynecol Oncol 1997; 65: 158-63.
9. Silverberg SG, M ajor FJ, B lessing JA, F etter B, A skin FB, Liao S-Y, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990; 9: 1-9.
10. Villena-Heinsen C, D iesing C, F ischer D, G riesinger D, Maas G, Diedrich N, et al. Carcinosarcomas-a retrospective analysis of 21 patients. Anticancer Res 2006; 26: 4817-23.
11. Pautier P, Rey A, H aie-Meder C, K erbrat P, D utel J L, Gesta P, et al. Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: Results of a case-control study with radiotherapy alone. Int J Gynecol Cancer 2004; 14: 1112-7.
12. Odunsi K, Moneke V, T ammela J, Ghamande S, Seago P, Driscoll D, et al. Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: Results oFlong-term follow-up. Int J Gynecol Cancer 2004; 14: 659-64.
13. Nordal RR, K ristensen GB, S tenwig A E, N esland JM, Pettersen EO, Trop é CG. An evaluation of prognostic factors in uterine carcinosarcoma. Gynecol Oncol 1997; 67: 316-21.
14. Sorbe B, J ohansson B. P rophylactic pelvic irradiation as part of primary therapy in uterine sarcomas. Int J Oncol 2008; 32: 1111-7.
15. Chiyoda T, Tsuda H, T anaka H, K ataoka F, N omura H, Nishimura S, et al. Expression profiles of carcinosarcomas of the uterine corpus-are these similar to carcinoma or sarcoma? GeneSchromosomes Cancer 2012; 51: 229-39.
16. Morice P, R odrigueSa, Pautier P, Rey A, Camatte S, Atallah D, et al. Surgery for uterine sarcoma: Review of the literature and recommendations for the standard surgical procedure. Gyn Obstet Fert 2003; 31: 147-50.
17. Brooks S E, Z han M, C ote T, B aquet C R. S urveillance, epidemiology, anDend resultSanalysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 2004; 93: 204-8.
18. Le T. A djuvant pelvic radiotherapy for uterine carcinosarcomas in a high risk population. Eur J Surg Oncol 2001; 27: 282-5.
19. Ferrer F, Sabater S, F arrus B, G uedea F, R ovirosa F, Anglada L, et al. Impact of radiotherapy on local controLand survival in uterine sarcomas: A retrospective study from the Group Oncologic Catala-Occita. Int J Radiat Oncol Biol Phys 1999; 44: 47-52.
20. Knocke TH, K ucera H, D orfl er D, P okrajac B, P otter R. Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri. Cancer 1998; 83: 1972-9.
21. Chi DS, M ychalczak B, Saigo PE, Rescigno J, B rown CL. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcomas. Gynecol Oncol 1997; 65: 493-8.
22. Kushner DM, W ebster K D, B elinson JL, R ybicki LA, Kennedy AW, Markman M. Safety anDefficacy of adjuvanTsingle-agent ifosfamide in uterine sarcoma. Gynecol Oncol 2000; 78: 221-7.
23. Toyoshima M, A kahira J, M atsunaga G, N iikura H, I to K, Yaegashi N, et al. Clinical experience with combination paclitaxeLand carboplatin therapy for advanced or recurrent carcinosarcomas of the uterus. Gynecol Oncol 2004; 94: 774-8.
24. Wolfson AH, B rady M F, R ocereto T, M annel R S, L ee Y C, Futoran RJ, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcomas (CS) of the uterus. Gynecol Oncol 2007; 107: 177-85.
25. Menczer J, L evy T, P iura B, C hetrit A, A ltaras M, M eirovitz M, et al. A comparison between different postoperative modalities of uterine carcinosarcomas. Gynecol Oncol 2005; 97: 166-70.
26. Kanjeekal S, C hamberSa, F ung F MK, V erma S. S ystematic therapy for advanced uterine sarcoma: A systematic review of the literature. Gynecol Oncol 2005; 97: 624-37.
27. Galaal K, G odfrey K, N aik R, K ucukmetin A, B ryant A. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcomas. Cochrane Database Syst Rev 2011; 19: CD006812.
28. Makker V, A bu-Rustum NR, A lektiar KM, A ghajanian CA, Zhou Q, IasonoSa, et al. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcomas. Gynecol Oncol 2008; 111: 249-54.
29. McCluggage W G. U terine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002; 12: 687-90.
30. Einstein M H, K lobocista M, H ou J Y, L ee S, M utyala S, Mehta K, et al. Phase II trial of adjuvant pelvic radiation " sandwiched " between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma. Gynecol Oncol 2012; 124: 26-30.
31. Livasy CA, Reading FC, M oore DT, B oggess JF, L ininger RA. EGFRexpression and HER2/neu overexpression/ amplification in endometrial carcinosarcomas. Gynecol Oncol 2006; 100: 101-6.
32. Raspollini M R, S usini T, A munni G, Paglierani M, Castiglione F, Garbini F, et al. Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: A marker for potential molecularly targeted treatment? Int J Gynecol Cancer 2006; 16: 416-22.
33. Gurumurthy M, S omoye G, Cairns M, Parkin DE. A n update on the management of uterine carcinosarcomas. Obstet Gynecol Surv 2011; 66: 710-6.